Non-Peptide Cholecystokinin-B/Gastrin Receptor Antagonists Based on Bicyclic, Heteroaromatic Skeletons

A series of potent and selective cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo2.2.2octane (BCO) skeleton which have recently been described were found to show species-dependent behavior when examined in rat and dog models. We now report the discovery of compounds in which the BCO skeleton has been replaced with bicyclic, heteroaromatic frameworks, such as a 5,6-disubstituted indole or benzimidazole. These new ligands maintain the affinity and selectivity profile of the previous compounds in vitro but show a much more consistent behavior pattern in vivo. Representative examples of this class of compound have been shown to inhibit pentagastrin-stimulated acid secretion when administered intravenously at doses of 0.1 mumol kg-1 or less.